InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

Sodium-glucose cotransporter 2 inhibition with dapagliflozin ameliorates extracellular volume expansion in diabetic kidney dise

T Masuda et al.
Used Parameters : TBW, ICE, ECW, ECW/TBW, Segmental ECW/TBW

Publication Year : 2017

Country : Japan

Journal : OJ Diabetes & Obesity Management

Background: Sodium-glucose cotransporter (SGLT) 2 inhibitors, a new class of antidiabetic drugs, have diuretic properties, but their effects on urinary Na excretion and the fluid status have not been fully evaluated. Methods: Diabetic kidney disease (DKD) patients with fluid retention were enrolled in this study. The SGLT2 inhibitor dapagliflozin was administered in addition to conventional treatment. Blood and 24-h urine samples were collected before dapagliflozin dosing on day 0 and afterwards on days 2 and 7. The fluid volume was …
Full text